FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 406 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Woman Has Unnecessary Double Mastectomy and Narrowly Avoids Hysterectomy After Bad... March 27, 2019 Trialling a new way to boost CAR T-cell therapy June 23, 2021 Study Adds to Debate about Mammography in Older Women September 12, 2023 Reflections on My First Year as NCI Director November 1, 2018 Load more HOT NEWS How Music Can Help You Cope During Cancer: An Expert Perspective Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and... Immunotherapy’s Skin Side Effects: Are Microbes to Blame? EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide
